Ovid Therapeutics Inc.
Gaboxadol for therapeutic treatment of 1p36 deletion syndrome
Last updated:
Abstract:
Methods and pharmaceutical compositions containing gaboxadol or a pharmaceutically acceptable salt thereof for treating 1p36 deletion syndrome are provided.
Status:
Grant
Type:
Utility
Filling date:
18 Dec 2020
Issue date:
21 Jun 2022